Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
<h4>Background</h4>Docetaxel is an established first-line therapy to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved for use after docetaxel failure, with improved survival. National Institute for Health and Clinical Exce...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Public Library of Science (PLoS)
2013
|
| Subjects: | |
| Online Access: | https://doaj.org/article/4604469ff4ee41d0af833205905effe0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|